ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche. Trastuzumab emtansine comprises ImmunoGen's DM1 cancer cell-killing agent linked to the trastuzumab antibody developed by Genentech, a member of the Roche Group, using ImmunoGen's method of attachment. It is in global development by Roche under an agreement between ImmunoGen and Genentech. Roche plans to apply this year for marketing approval of trastuzumab emtansine in the US and Europe using EMILIA data. ???
The EMILIA 991-patient trial compares trastuzumab emtansine, used alone, to lapatinib (Tykerb?) plus capecitabine (Xeloda?) for the treatment of HER2-positive metastatic breast cancer that has progressed after treatment with trastuzumab (Herceptin?) and a taxane in any setting (early or metastatic disease).
Among the study findings reported are:
ps i love you ray charles cheney heart transplant weather san diego unitarian new black panther party lost in space
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.